Merck KGaA Rebif Faces Irreversible Decline; Avelumab Update Seen Soon
This article was originally published in The Pink Sheet Daily
Sales of the German multinational’s best-selling MS product sharply declined in the second quarter, but higher investment is likely to boost its research pipeline of early- and late-stage products.
You may also be interested in...
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.